Preparation of the self-accelerating photocatalytic self-cleaning carboxymethyl cellulose sodium-based hydrogel for removing cationic dyes

Hydrogels loaded with photocatalysts have shown great potential in effectively degrading dye wastewater. In this work, carboxymethyl cellulose sodium-based hydrogels loaded with nitrogen-doped graphene oxide-zinc oxide-zinc peroxide (NGO-ZnO-ZnO2) were synthesized using hydrothermal reaction and in-situ synthesis method. NGO acts as an electron mediator, suppressing the recombination of photoinduced electrons and holes. ZnO2 decomposes to generate hydrogen peroxide (H2O2), promoting a self-enhanced photocatalytic reaction. Carboxymethyl cellulose sodium (CMC) acts as a dispersant, improving the uniformity and stability of NGO-ZnO-ZnO2 within the hydrogel. The results demonstrate that NGO-ZnO-ZnO2 exhibits high photocatalytic degradation efficiency towards methyl orange (MO) (10 mg/L) and rhodamine B (RhB) (50 mg/L), with degradation rates of 99.99 % (200 min) and 99.26 % (160 min), respectively. The carboxymethyl cellulose sodium-based hydrogel achieves a photocatalytic degradation rate of 95.85 % (220 min) for RhB (10 mg/L). After 5 cycles of repeated photocatalytic tests, the degradation efficiency of the hydrogel towards RhB reaches 80.81 %. This work provides a low-cost and convenient method for constructing novel hydrogel carriers with high photocatalytic stability and efficiency.

A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy

BACKGROUND

The selectively accumulate in tumor site and completely release drug within cancer cells great limit the therapeutic effect of nano-drug delivery system. Moreover, absence of appropriate biomarker is one of the major challenges for prostate specific membrane antigen negative (PSMA (-)) prostate cancer therapy.

RESULTS

Herein, a PSMA (-) prostate cancer specific targeted and intracellular reactive oxygen species (ROS) amplification for ROS-responsive self-accelerating drug release nanoplatform (ATD-NPs) was developed. ATD-NPs was formed by three parts, including PSMA (-) prostate cancer specifically targeted part (DUP-PEG-DSPE), ROS-sensitive doxorubicin (DOX) polymeric prodrug (P(L-TK-DOX)), and the ROS generation agent (α-tocopheryl succinate, α-TOS); and this delivery system is expected to enhance PSMA (-) prostate cancer therapeutic effect, increase selective accumulation at tumor site and overcome intracellular incomplete drug release. After administration i.v injection, ATD-NPs could specifically accumulate in tumor site and markedly be internalized by cancer cells based on the DUP-1 (a PSMA (-) cancer cells specific target peptide). Subsequently, ATD-NPs could be dissociated under the high concentration reactive oxygen species (ROS) condition, resulting in DOX and α-TOS release. Then, the released α-TOS could be reacted with mitochondria to produce ROS, which in turn accelerating the release of drugs. Finally achieved the purpose of enhancing therapeutic efficacy and reducing side effect. Both in vitro and in vivo experiments demonstrated that the combination of tumor actively-targeted and self-amplifying ROS-responsive drug release showed more significant antitumor activity in the human PSMA (-) prostate cancer.

CONCLUSION

The described technology unifies the tumor actively targets, self-amplified drug release, and excellent biocompatibility into one formulation, are promising for cancer treatment.